Laddar...
Bronchopleural fistula in squamous cell lung cancer following anlotinib treatment: A case report
Anlotinib is a multi-target tyrosine kinase inhibitor and has been approved for the treatment of patients with advanced non-small cell lung cancer. The most common adverse events of this treatment include hypertension, fatigue, thyroid-stimulating hormone elevation, hypertriglyceridemia, hand-foot s...
Sparad:
| I publikationen: | Mol Clin Oncol |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
D.A. Spandidos
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6870048/ https://ncbi.nlm.nih.gov/pubmed/31798876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1939 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|